OP2 Prophylactic, N-Acetylcysteine unsuccessful in influencing plasma antioxidant capacity in a parallel-group randomized controlled trial of patients with chronic kidney disease stage III; implications for contrast induced nephropathy. (5th April 2020)

• Record Type: Journal Article
• Authors: Raja, KI; Hickson, K; Treweeke, AT; Rushworth, G; Morrison, E; Sandilands, E; Cobley, JN; McEneaney, D; Eddleston, M; Megson, IL
• Is Part Of: Heart. Volume 106(2020)Supplement 1
• Page Start: A1
• Page End: A1
• Publication Date: 2020-04-05
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2020-SCF.2
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Introduction: N-acetyl-L-cysteine (NAC) has been proposed as a prophylactic for the prevention of contrast induced nephropathy (CIN), a common, undesirable complication following the administration of contrast media in patients with diabetes and chronic kidney disease (CKD). 1 However, clinical trial results have failed to consistently demonstrate beneficial qualities of NAC in this setting. The proposed mechanism by which NAC has been proposed to be effective is via antioxidant activity, but NAC itself is not a powerful antioxidant. Intracellular conversion of NAC to glutathione (GSH) is essential for antioxidant effects (Treweeke, Winterburn et al. 2012). We tested the hypotheses that whilst oral or intravenous NAC fails to increase antioxidant activity in the plasma of CKD stage III patients undergoing elective coronary angiography, intracellular conversion of NAC to GSH can occur in buffy coat cells deficient in GSH. Methods: 66 patients with CKD stage III undergoing elective coronary angiography were recruited to a parallel-group randomized controlled trial. Each patient was randomised to receive NAC (i.v.; 50 mg/kg/hr infusion for 2 h, followed by 20 mg/kg/hr infusion for a further 5 h), or NAC (oral; 1200 mg twice daily, commencing the day before contrast exposure) or placebo upon visiting the Clinical Research Facility. On the day of the study, patients were infused with PAH and inulin to regulate several renal function parameters and infused with contrast media prior to the coronary angiography (Sandilands, Cameron et al. 2012). Plasma and paired buffy coat samples were collected at several time points during the trial in order to measure various clinical parameters, along with intracellular and plasma thiol concentrations and the plasma antioxidant capacity (oxygen radical antioxidant capacity; ORAC). Results: Plasma NAC concentrations peaked at 348 µM following infusion of NAC of the 11 data sets included; the corresponding peak concentrations were 2.8 µM following oral NAC treatment from 7 data sets. No comparable increase in the plasma compartment ORAC antioxidant capacity was measured in any of the treatment groups. Equally, contrast infusion itself did not significantly reduce antioxidant capacity in plasma, even in the placebo group. Buffy coat measures showed that there was a significant increase of intracellular GSH some patients, although the effect was variable. Also, no clear additional benefit was witnessed by increasing plasma NAC >10-fold through infusion of NAC over oral administration. Conclusion: NAC fails to influence ORAC antioxidant capacity in the plasma compartment of CKD stage III patients receiving contrast media. Our results question the importance of oxidative stress in contrast-induced nephropathy. Furthermore, the findings fail to demonstrate a direct antioxidant impact of NAC in the plasma compartment. Instead, we found that NAC can increase intracellular GSH in some deficient individuals, which might carry some benefits in terms of detoxification and question the antioxidant hypothesis related to contrast-induced nephropathy and NAC. References: Sandilands EA, Cameron S, Paterson F, Donaldson S, Briody L, Crowe J, Donnelly J, Thompson A, Johnston NR, Mackenzie I, Uren N, Goddard J, Webb DJ, Megson IL, Bateman N, Eddleston M. 'Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol.' BMC Clin Pharmacol 2012;12:3. Treweeke AT, Winterburn TJ, Mackenzie I, Barrett F, Barr C, Rushworth GF, Dransfield I, MacRury SM, Megson IL. 'N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial.' Diabetologia 2012;55(11):2920–2928.